Click on headlines below to download research

Large response benefit consistent in ALICE trial
Oryzon Genomics | 15/06/2021

On 11 June 2021, Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at the virtual Congress of the…

Termination of coverage
Termination of coverage | 30/03/2021

Edison Investment Research is terminating coverage on EJF Investments (EJFI), ROVI Laboratorios Farmaceuticos (ROVI) and SDX Energy (SDX). Please note…

2021: A pinnacle year
Laboratorios Farmacéuticos ROVI | 10/03/2021

Laboratorios Farmacéuticos ROVI (ROVI) has reported a strong set of FY20 results, with all pillars of the business contributing to revenue growth…

Response rates consistently high in ALICE trial
Oryzon Genomics | 11/12/2020

Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at this year’s virtual ASH conference (5–8…

All good things come in threes
Laboratorios Farmacéuticos ROVI | 10/12/2020

Laboratorios Farmacéuticos ROVI’s (ROVI’s) recent capital markets day (CMD) highlighted the strong positioning of its three key franchises.…

Momentum continues across key franchises
Laboratorios Farmacéuticos ROVI | 11/11/2020

Reported 9M20 numbers highlight continual strength in sales across key franchises and ongoing margin expansion. ROVI reported operating revenue of €302.1m…

Final update from Phase IIa CLEPSIDRA trial
Oryzon Genomics | 28/09/2020

On 17 September Oryzon presented an update from its Phase IIa CLEPSIDRA trial with iadademstat, a selective LSD1 inhibitor, in combination with platinum/etoposide…

Termination of coverage
Termination of coverage | 07/09/2020

Edison Investment Research is terminating coverage on Abacus Health Products (ABCS), ADL Bionatur (BNT), ASIT Biotech (ASIT), GAME Digital (GMD), International…